Dr. Zulueta on the Non-Invasive LuCED Test for Detection of Early Stage Lung Cancer

Javier Zulueta, MD
Published: Monday, Dec 05, 2016



Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses the LuCED test, a non-invasive tool used to detect early stage lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Low-dose computed tomography (LDCT) screening for lung cancer often leads to follow-up scans for indeterminate nodules. The non-invasive LuCED test may resolve nodule findings and reduce LDCT false positives. When using this test, patient sputum is analyzed by the Cell-CT, which computes 3D images of single cells, allowing measurement of 3D structural biomarkers to identify potentially abnormal cells.

According to Zulueta's findings, the LuCED test demonstrates accurate detection of early stage lung cancer with the potential of detecting pre-cancerous conditions of the lung. These results suggest that suspicious nodules may be efficiently reconciled by this novel tool when used with LDCT.


Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses the LuCED test, a non-invasive tool used to detect early stage lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Low-dose computed tomography (LDCT) screening for lung cancer often leads to follow-up scans for indeterminate nodules. The non-invasive LuCED test may resolve nodule findings and reduce LDCT false positives. When using this test, patient sputum is analyzed by the Cell-CT, which computes 3D images of single cells, allowing measurement of 3D structural biomarkers to identify potentially abnormal cells.

According to Zulueta's findings, the LuCED test demonstrates accurate detection of early stage lung cancer with the potential of detecting pre-cancerous conditions of the lung. These results suggest that suspicious nodules may be efficiently reconciled by this novel tool when used with LDCT.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x